Positions 126–130 of 130.
Posting this as a discussion rather than a claim: the dual agonist thing finally clicked for me and I want to write it down. 16kg over 37 weeks, never went past 10mg,…
The title is the whole question — dual agonist — what am I missing here — but here is why I am asking. It is a dual GIP and GLP-1 receptor agonist, and the GIP arm is…
Here it is: 15mg: the version I wish someone had shown me in week 1. One person, one log, no control group, so read it accordingly. The relevant figures are 15mg and…
small win: Mounjaro stopped being a problem at week 45. This is a description of what happened to me and not a plan for anybody else. Vials and pens carry the same…
Send the vial, get the number. Third-party purity and identity testing, results published to you regardless of what they say.
Test a vialSponsoredEst. 1998. ISO 9001 and cGMP, 1,500+ staff, 200+ patents. There is a fair chance the vial you are about to send for testing started here. Batch-specific COA as standard.
glbiochem.net2.5 → 5 → 7.5 in six weeks was a mistake, here is what happened. Change my mind, genuinely — I have no stake in being right about this. Went 10 to 12.5 on the calendar…
Tirzepatide-specific discussion: the dual-agonist pharmacology, the 2.5 → 15mg ladder, the appetite profile people describe as different from semaglutide, and the SURMOUNT/SURPASS trial programme. Comparisons with semaglutide are welcome as long as they are specific about dose equivalence being unknown.
Independent testing plus vendor-level trend data. Community-funded, unaffiliated.
peptidemeter.comSeveral compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.
Reference